Newton Sérgio de Carvalho

Author

Also Known As

C M Roteli-Martins, Carvalho, Newton S. de, Carvalho, Newton Sérgio de, Johanna Palmroth, N CARVALHO, N Carvalho, N. Carvalho, N.S. de Carvalho, NEWTON SÉRGIO DE CARVALHO, NSC Carvalho

144

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Universidade Federal do Paraná Universidade Estadual de Campinas (UNICAMP)Hospital de Clínicas de Porto Alegre Hospital de Clínicas Universidade Federal do Paraná GlaxoSmithKline (United States)

About

Newton Sérgio de Carvalho is an author at Universidade Federal do Paraná specializing in medicine, human papillomavirus vaccines, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	3.8K
2	Public Health	6	6	827
3	Epidemiology	5	5	155
4	Health Sciences	1	1	59
5	Microbiology	1	1	59

Newton Sérgio de Carvalho

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler, The Lancet VaccinationVaccine SafetyVaccine DevelopmentHuman Papillomavirus VaccinesVirology	2004	1.6K
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Jorma Paavonen, David Jenkins, F. Xavier Bosch, The Lancet VaccinationVaccine SafetyInterim AnalysisPreventive MedicinePhase Iii Double-blind	2007	1.3K
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler, The Lancet Oncology VaccinationCervical Cancer ScreeningHpv-16/18 As04-adjuvanted VaccineCervical CancerCervical Health	2011	693
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Paulo Naud, Cecília Roteli-Martins, Newton Sérgio de Carvalho, Human Vaccines & Immunotherapeutics	2014	245
Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M. Garland, PLoS ONE	2013	206
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine Cecília Roteli-Martins, Paulo Naud, P. De Borba, Human Vaccines & Immunotherapeutics	2012	188
Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: <i>Post‐hoc</i> analysis from a randomized controlled trial Suzanne M. Garland, Jorma Paavonen, Unnop Jaisamrarn, International Journal of Cancer	2016	100
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial Édith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, Gynecologic Oncology	2012	81
Association Between COVID-19 Pregnant Women Symptoms Severity and Placental Morphologic Features Patrícia Zadorosnei Rebutini, Aline Cristina Zanchettin, Emanuele Therezinha Schueda Stonoga, Frontiers in Immunology	2021	72
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials Joseph E. Tota, Frank Struyf, Marko Merikukka, JNCI Journal of the National Cancer Institute	2016	63

Page 1